Generic Name: eculizumab
Brand Name: Soliris
Manufacturer: Alexion Pharma Canada Corp.
Therapeutic Area: Neuromyelitis optica spectrum disorder
Indications: For the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.
Manufacturer Requested Reimbursement Criteria1: For the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.
Submission Type: Initial
Project Status: Complete
Companion Diagnostics: No
Date Recommendation Issued: August 19, 2020
Recommendation Type: Reimburse with clinical criteria and/or conditions
Fee Schedule: Schedule B
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
|Call for patient input open||January 24, 2020|
|Call for patient input closed||March 16, 2020|
- Patient input submission received from Multiple Sclerosis Society of Canada
|Submission received||February 25, 2020|
|Submission accepted||March 10, 2020|
|Review initiated||March 11, 2020|
- Selected for CADTH/INESSS Joint Clinician Engagement
|Draft CADTH review report(s) provided to sponsor for comment||June 03, 2020|
|Deadline for sponsors comments||June 12, 2020|
|CADTH responses on draft review report(s) provided to sponsor||July 03, 2020|
|Expert committee meeting (initial)||July 15, 2020|
|Draft recommendation issued||July 28, 2020|
|End of embargo period||August 12, 2020|
|Final recommendation issued to sponsor and drug plans||August 19, 2020|
|Final recommendation posted||August 24, 2020|
|Deadline for sponsor to submit redaction requests on draft CADTH review report(s)||September 02, 2020|
|CADTH review report(s) posted||October 21, 2020|